Evidence map›Paper›PMID 42606854›Full record

ArticleJAMA pediatrics2026

Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants.

Ushma Wadia, Madeline M Ong, Sarah N Cox, Huong Le, Damien Foo, Shauna Wolf Mankiewicz, Jeremy Carr, Helen S Marshall, Julia E Clark, Philip N Britton and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ushma WadiaWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
Madeline M OngWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
Sarah N CoxPfizer, New York, New York.
Huong LeWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
Damien FooWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
Shauna Wolf MankiewiczPfizer, New York, New York.
Jeremy CarrMonash Children's Hospital, Monash University, Melbourne, Victoria, Australia.
Helen S MarshallCollege of Health, Adelaide University, North Adelaide, South Australia, Australia.
Julia E ClarkDepartment of Infectious Diseases, Children's Health Queensland, Brisbane, Queensland, Australia.
Philip N BrittonThe Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Brendan McMullanDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia.
Ye TanPfizer, New York, New York.
Zirke WiidPfizer Australia, Sydney, New South Wales, Australia.
Shidan TosifInfection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Te-Yu HungRoyal Darwin Hospital, Menzies School of Health Research, Darwin, Northern Territory, Australia.
Hannah C MooreWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
Kyla HayfordPfizer, New York, New York.
Alejandro CanéPfizer, New York, New York.
Deshayne B FellPfizer, New York, New York.
Jessica E AtwellPfizer, New York, New York.
Peter C RichmondWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
STREETON Study Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks' gestation as the primary, year-round strategy to prevent RSV disease in infants 6 months of age or younger. Objective: To estimate effectiveness of RSVpreF vaccination during pregnancy against infant RSV hospitalization in Australia. Design, Setting, and Participants: This retrospective case-control study with a test-negative design was conducted in 9 hospitals across Australia with year-round respiratory testing for acute respiratory illness (ARI) among infants born from 28 weeks' gestation and hospitalized with ARI at 6 months of age or younger, March 1, 2025, through February 28, 2026. Data were analyzed March 2026 through May 2026. Exposure: Maternal RSVpreF vaccination administered from 28 weeks' gestation and 14 days or more before delivery. Main Outcomes and Measures: Maternal RSVpreF effectiveness was evaluated against hospitalization for RSV lower respiratory tract disease (RSV-LRTD, primary objective), severe RSV-LRTD, and RSV-ARI. Logistic regression with confounder adjustment was used to calculate vaccine effectiveness (VE) as (1 - adjusted odds ratio) × 100%. Results: Of 1012 infants hospitalized with ARI, 655 had LRTD, with 114 of 386 case infants (30%) and 171 of 269 control infants (64%) born to RSVpreF-vaccinated mothers (median [IQR] gestational age at vaccination, 31 weeks [29-33]). Median (IQR) maternal age at delivery was 32 years (29-35). Median (IQR) age of infants hospitalized for LRTD was 52 days (30-89); 495 of 655 (76%) were aged 3 months or younger. VE against RSV-LRTD hospitalization was 77.8% (95% CI, 66.4%-85.3%) among infants from birth through 6 months of age, 80.2% (95% CI, 71.1%-86.5%) among infants from birth through 3 months of age, 86.3% (95% CI, 79.0%-91.1%) among infants from birth through 2 months of age, and 68.2% (95% CI, 42.2%-82.5%) among infants older than 2 months through 4 months of age. Comparable VE among infants aged 6 months or younger was observed for severe RSV-LRTD (80.4%; 95% CI, 54.4%-91.6%) and RSV-ARI (80.8%; 95% CI, 70.4%-87.6%) hospitalization, with similar age-specific trends. VE was consistent across stratifications by gestational age at vaccination, vaccination to delivery time interval, and proximal administration with other vaccines during pregnancy. Descriptively, among all infants hospitalized with ARI, 161 of 499 (32%) born to RSVpreF-unvaccinated mothers had severe LRTD, while 87 of 513 (17%) born to RSVpreF-vaccinated mothers had severe LRTD. Conclusions and Relevance: Findings in this case-control study demonstrate high year-round effectiveness of RSVpreF vaccination against RSV-associated hospitalization in infants 6 months of age or younger in the first year following introduction in Australia, with the highest VE observed in the earliest age intervals. Future analyses with larger sample sizes will evaluate VE among additional subgroups.

Identifiers

PMID42606854
PMCPMC13482632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.